Therapeutic Asset Ratings
6,308 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Venetoclax
Acquired Polycythemia Vera
M.D. Anderson Cancer Center
P1/2
CCC
(48)
Venetoclax
Cellular Phase Chronic Idiopathic Myelofibrosis
M.D. Anderson Cancer Center
P1/2
CCC
(48)
Venetoclax
T-Cell Prolymphocytic Leukemia
Jonsson Comprehensive Cancer Center
P1/2
CCC
(48)
vg2025
Colorectal Cancer
Akeso
P1/2
CCC
(48)
(+)-Vincristine
EZB-MYC+ Diffuse Large B-Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
P1/2
CCC
(48)
(+)-Vincristine
Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia
M.D. Anderson Cancer Center
P1/2
CCC
(48)
Vincristine Sulfate
Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia
ECOG-ACRIN Cancer Research Group
P1/2
CCC
(48)
Vitamin D
Drug Allergy
rana alaaeldin aly ibrahim nasr
P1/2
CCC
(48)
Vls-1488
Endometrial Cancer
Volastra Therapeutics, Inc.
P1/2
CCC
(48)
Vls-1488
Ovarian Carcinosarcoma
Volastra Therapeutics, Inc.
P1/2
CCC
(48)
Vls-1488
Squamous Cell Lung Carcinoma
Volastra Therapeutics, Inc.
P1/2
CCC
(48)
Vls-1488
Uterine Carcinosarcoma
Volastra Therapeutics, Inc.
P1/2
CCC
(48)
Vorbipiprant
Digestive System Cancer
Rottapharm Biotech
P1/2
CCC
(48)
Vorbipiprant
Colorectal Cancer
Rottapharm Biotech
P1/2
CCC
(48)
Vorinostat
Acute Leukemia
University of Michigan Rogel Cancer Center
P1/2
CCC
(48)
White Blood Cells/Granulocytes
Disease Related To Hematopoietic Stem Cell Transplant
University of Manchester
P1/2
CCC
(48)
wj05129
Cancer
Suzhou Junjing BioSciences Co., Ltd.
P1/2
CCC
(48)
wj13404 tablets
Non-Small Cell Lung Carcinoma
Suzhou Junjing BioSciences Co., Ltd.
P1/2
CCC
(48)
Wve-004
Frontotemporal Dementia
Wave Life Sciences USA, Inc.
P1/2
CCC
(48)
Xanomeline
Schizoaffective Disorder
New York State Psychiatric Institute
P1/2
CCC
(48)
xnw5004
Metastatic Prostate Carcinoma
Evopoint Biosciences Inc.
P1/2
CCC
(48)
yl-13027
Malignant Pancreatic Neoplasm
Shanghai YingLi Pharmaceutical Co. Ltd.
P1/2
CCC
(48)
Yttrium (90 Y)
Disease Related To Solid Organ Transplantation
University Health Network, Toronto
P1/2
CCC
(48)
Zalifrelimab
Head And Neck Squamous Cell Carcinoma
ImmunoGenesis
P1/2
CCC
(48)
Zelenectide Pavedotin
Ovarian Neoplasm
BicycleTx Limited
P1/2
CCC
(48)
Showing 2026 to 2050 of 6,308 assets
Previous
Page 82 of 253
Next